Summit Therapeutics Inc.

For the period ended Mar 31, 2026. Filed Apr 30, 2026.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Mar 31, 2026 · Filed Apr 30, 2026

SMMT$17.83-0.1%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Statements of Stockholders' Equity

(in thousands, except share data)

Common Stock · Additional Paid-In Capital · Accumulated Other Comprehensive Loss · Accumulated Deficit · Total Stockholders' Equity
Shares · Amount
Balance at December 31, 2025	775,371,200	$7,754	$2,947,805	$(2,540)	$(2,294,159)	$658,860
Issuance of common stock under stock purchase plans and exercise of stock options	646,274	6	3,791	—	—	3,797
Stock-based compensation	—	—	72,791	—	—	72,791
Net other comprehensive loss	—	—	—	(92)	—	(92)
Net loss	—	—	—	—	(189,424)	(189,424)
Balance at March 31, 2026	776,017,474	$7,760	$3,024,387	$(2,632)	$(2,483,583)	$545,932

Common Stock · Additional Paid-In Capital · Accumulated Other Comprehensive Loss · Accumulated Deficit · Total Stockholders' Equity
Shares · Amount
Balance at December 31, 2024	737,626,004	$7,376	$1,598,230	$(2,285)	$(1,214,573)		$388,748
Issuance of common stock under stock purchase plans and exercise of stock options and warrants (2)	3,983,386	40	7,637	—	—		7,677
Stock-based compensation	—	—	11,096	—	—		11,096
Net other comprehensive loss	—	—	—	(278)		(278)
Net loss	—	—	—	—	(62,913)		(62,913)
Balance at March 31, 2025	741,609,390	$7,416	$1,616,963	$(2,563)	$(1,277,486)		$344,330

(2) Refer to Note 11 – Related Party Transactions.

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.